跳至主要内容
临床试验/NCT00453401
NCT00453401已完成2 期

The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

NanoBio Corporation56 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2007年2月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
1,000
试验地点
56
主要终点
Time to healing as assessed by the subject.

研究概览

简要总结

Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 to 80 years of age of either gender
  • Good general health
  • History of recurrent herpes labialis with at least 3 episodes per year

排除标准

  • Pregnant and/or nursing female
  • Lesions or irritation on or around the lips that would interfere with recognition of a herpes labialis attack
  • Treatment with topical steroids, antivirals, or new topical products on or around the lips in the week prior to the onset of an attack
  • Known allergies to topical creams, ointments or medications.
  • Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Time to healing as assessed by the subject.

次要结局

  • Percent of subjects with healing by days 3, 4,and 5 as assessed by the subject.

研究者

申办方类型
Industry

研究点 (56)

Loading locations...

相似试验